Advertisement

Medical Oncology

, 30:562 | Cite as

Inverse correlation between Naa10p and MMP-9 expression and the combined prognostic value in breast cancer patients

  • Yan Zeng
  • Caiyun Liu
  • Bin Dong
  • Yuanyuan Li
  • Beihai Jiang
  • Ye Xu
  • Lin Meng
  • Jian Wu
  • Like Qu
  • Chengchao ShouEmail author
Original Paper

Abstract

To analyze the expression profiles of N-a-acetyltransferase 10 protein (Naa10p/ARD1) and matrix metalloproteinase 9 (MMP-9) in human breast cancer and evaluate their possible prognostic values in breast cancer patients. Quantitative RT-PCR was used to evaluate mRNA expression of Naa10p and MMP-9 in 55 cases of fresh breast cancer tissues, and immunohistochemistry was performed for detecting Naa10p and MMP-9 proteins on breast cancer with tissue microarray containing 80 specimens. Furthermore, Naa10p and MMP-9 were measured in 253 breast cancer tissues from patients with up to 15-year follow-up. Survival curves were generated using the Kaplan–Meier method. Multivariate analysis was performed by using the Cox proportional hazard regression model to assess the prognostic values of Naa10p and MMP-9. Both Naa10p and MMP-9 expression in breast cancer tissues were significantly higher than those in the matched non-cancerous tissues (p = 0.000 for both). There was an inverse correlation between Naa10p and MMP-9 expression at mRNA and protein levels (p = 0.000 for both). Patients with MMP-9-positive expression had a poorer overall survival (OS) and disease-free survival (DFS) than those with MMP-9-negative expression (p = 0.001 for both). However, patients with Naa10p-positive expression had better OS and DFS (p = 0.000 for both). In addition, Naa10p-positive/MMP-9-negative patients had the best OS and DFS (p = 0.000 for both). In multivariate survival analysis, TNM stage, Naa10p expression, MMP-9 expression, and combined expression status of Naa10p/MMP-9 were independent prognostic factors related to OS (p = 0.000, 0.007, 0.012, and 0.000, respectively) and DFS (p = 0.000, 0.002, 0.014, and 0.000, respectively).The expression level of Naa10p was inversely correlated with that of MMP-9 in human breast cancer samples. Combined analysis of Naa10p and MMP-9 had a significantly increased value for determining the prognosis of breast cancer patients.

Keywords

Naa10p MMP-9 Correlation Breast cancer Prognosis 

Notes

Acknowledgments

The authors thank Dr. Yun-tao Xie (Breast Center, Peking University Cancer Hospital & Institute) for providing fresh breast cancer samples. This study was supported by National 973 Program of China (2009CB521805) and National Natural Science Foundation of China (81071658).

Conflict of interest

We declare that we have no conflict of interest.

References

  1. 1.
    Hortobagyi GN, de la Garza Salazardela J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6:391–401.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRefGoogle Scholar
  3. 3.
    Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.PubMedCrossRefGoogle Scholar
  5. 5.
    Arnesen T, Anderson D, Baldersheim C, et al. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J. 2005;386:433–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Seo JH, Cha JH, Park JH, et al. Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation. Cancer Res. 2010;70:4422–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Lim JH, Park JW, Chun YS. Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 2006;66:10677–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Kuo HP, Lee DF, Chen CT, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal. 2010;3:ra9.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee CF, Ou DS, Lee SB, et al. hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. J Clin Invest. 2010;120:2920–30.PubMedCrossRefGoogle Scholar
  10. 10.
    Fisher TS, Etages SD, Hayes L, et al. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J Biol Chem. 2005;280:17749–57.PubMedCrossRefGoogle Scholar
  11. 11.
    Arnesen T, Gromyko D, Pendino F, et al. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene. 2006;25:4350–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Yi CH, Sogah DK, Boyce M, et al. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol. 2007;179:619–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Hua KT, Tan CT, Johansson G, et al. N-alpha-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell. 2011;19:218–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Sugiura N, Adams SM, Corriveau RA. An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem. 2003;278:40113–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohkawa N, Sugisaki S, Tokunaga E, et al. N-acetyltransferase ARD1-NAT1 regulates neuronal dendritic development. Genes Cells. 2008;13:1171–83.PubMedGoogle Scholar
  16. 16.
    Ren T, Jiang B, Jin G, et al. Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett. 2008;264:83–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang B, Ren T, Dong B, et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol. 2010;177:1095–103.PubMedCrossRefGoogle Scholar
  18. 18.
    Yu M, Gong J, Ma M, et al. Immunohistochemical analysis of human arrest-defective-1 expressed in cancers in vivo. Oncol Rep. 2009;21:909–15.PubMedGoogle Scholar
  19. 19.
    Wang ZH, Gong JL, Yu M, et al. Up-regulation of human arrest-defective 1 protein is correlated with metastatic phenotype and poor prognosis in breast cancer. Asian Pac J Cancer Prev. 2011;12:1973–7.PubMedGoogle Scholar
  20. 20.
    Fridman R, Toth M, Pena D, et al. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res. 1995;55:2548–55.PubMedGoogle Scholar
  21. 21.
    Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem. 1995;64:1312–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Kohrmann A, Kammerer U, Kapp M, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer. 2009;9:188.PubMedCrossRefGoogle Scholar
  23. 23.
    Patel S, Sumitra G, Koner BC, et al. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem. 2011;44:869–72.PubMedCrossRefGoogle Scholar
  24. 24.
    Xu H, Jiang B, Meng L, et al. N-alpha-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis. 2012;33:1193–202.PubMedCrossRefGoogle Scholar
  25. 25.
    Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138–40.PubMedGoogle Scholar
  26. 26.
    Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.PubMedGoogle Scholar
  27. 27.
    Planaguma J, Liljestrom M, Alameda F, et al. Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol. 2011;42:57–67.PubMedCrossRefGoogle Scholar
  28. 28.
    Bendardaf R, Buhmeida A, Hilska M, et al. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest. 2010;28:38–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhao ZS, Wang YY, Ye ZY, et al. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res. 2009;15:589–96.PubMedCrossRefGoogle Scholar
  30. 30.
    Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241.PubMedCrossRefGoogle Scholar
  31. 31.
    Provatopoulou X, Gounaris A, Kalogera E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer. 2009;9:390.PubMedCrossRefGoogle Scholar
  32. 32.
    Patel BP, Shah SV, Shukla SN, et al. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007;29:564–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Liu Z, Li L, Yang Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270.PubMedCrossRefGoogle Scholar
  34. 34.
    Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene. 1993;8:395–405.PubMedGoogle Scholar
  35. 35.
    Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002;111:709–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Bilton R, Mazure N, Trottier E, et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem. 2005;280:31132–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Midorikawa Y, Tsutsumi S, Taniguchi H, et al. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res. 2002;93:636–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang Z, Guo J, Li Y, et al. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Proc Natl Acad Sci USA. 2012;109:3053–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yan Zeng
    • 1
    • 2
  • Caiyun Liu
    • 1
  • Bin Dong
    • 3
  • Yuanyuan Li
    • 1
  • Beihai Jiang
    • 4
  • Ye Xu
    • 5
  • Lin Meng
    • 1
  • Jian Wu
    • 1
  • Like Qu
    • 1
  • Chengchao Shou
    • 1
    Email author
  1. 1.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular BiologyPeking University Cancer Hospital & InstituteBeijingChina
  2. 2.Key Laboratory of Xinjiang Endemic and Ethnic Disease, Department of Biochemistry, School of MedicineShihezi UniversityXinjiangChina
  3. 3.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Center LaboratoryPeking University Cancer Hospital & InstituteBeijingChina
  4. 4.Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Minimally Invasive Gastrointestinal SurgeryPeking University Cancer Hospital & InstituteBeijingChina
  5. 5.Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Breast CenterPeking University Cancer Hospital & InstituteBeijingChina

Personalised recommendations